Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics (ALLO)
NASDAQ:ALLO
Total Valuation
Allogene Therapeutics has a market cap or net worth of $379.79M. The enterprise value is $413.95M.
Market Cap$379.79M
Enterprise Value$413.95M
Share Statistics
Allogene Therapeutics has 224,730,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding224,730,150
Owned by Insiders10.48%
Owned by Institutions31.02%
Financial Efficiency
Allogene Therapeutics’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -52.47%.
Return on Equity (ROE)-0.61
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-52.47%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee97.35
Profits Per Employee-1.14M
Employee Count226
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Allogene Therapeutics is ―. Allogene Therapeutics’s PEG ratio is 0.04.
PE Ratio―
PS Ratio18861.34
PB Ratio0.98
Price to Fair Value0.98
Price to FCF-2.06
Price to Operating Cash Flow-2.31
PEG Ratio0.04
Income Statement
In the last 12 months, Allogene Therapeutics had revenue of 22.00K and earned -257.59M in profits. Earnings per share was -1.32.
Revenue22.00K
Gross Profit22.00K
Operating Income-273.20M
Pretax Income-257.15M
Net Income-257.59M
EBITDA-243.33M
Earnings Per Share (EPS)-1.32
Cash Flow
In the last 12 months, operating cash flow was -158.34M and capital expenditures -643.00K, giving a free cash flow of -158.99M billion.
Operating Cash Flow-158.34M
Free Cash Flow-158.99M
Free Cash Flow per Share-0.71
Dividends & Yields
Allogene Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.64
52-Week Price Change18.18%
50-Day Moving Average1.53
200-Day Moving Average1.31
Relative Strength Index (RSI)53.62
Average Volume (3m)5.68M
Important Dates
Allogene Therapeutics upcoming earnings date is Mar 4, 2026, Before Open (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateMar 4, 2026
Ex-Dividend Date―
Financial Position
Allogene Therapeutics as a current ratio of 8.54, with Debt / Equity ratio of 27.00%
Current Ratio8.54
Quick Ratio8.54
Debt to Market Cap0.00
Net Debt to EBITDA-0.06
Interest Coverage Ratio-1.51K
Taxes
In the past 12 months, Allogene Therapeutics has paid 443.00K in taxes.
Income Tax443.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Allogene Therapeutics EV to EBITDA ratio is -1.77, with an EV/FCF ratio of -2.14.
EV to Sales19.57K
EV to EBITDA-1.77
EV to Free Cash Flow-2.14
EV to Operating Cash Flow-2.15
Balance Sheet
Allogene Therapeutics has $252.19M in cash and marketable securities with $85.14M in debt, giving a net cash position of $167.05M billion.
Cash & Marketable Securities$252.19M
Total Debt$85.14M
Net Cash$167.05M
Net Cash Per Share$0.74
Tangible Book Value Per Share$2.17
Margins
Gross margin is 0.00%, with operating margin of -1241813.64%, and net profit margin of -1170863.64%.
Gross Margin0.00%
Operating Margin-1241813.64%
Pretax Margin-1168850.00%
Net Profit Margin-1170863.64%
EBITDA Margin-1106031.82%
EBIT Margin-1168027.27%
Analyst Forecast
The average price target for Allogene Therapeutics is $6.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.50
Price Target Upside284.62% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-100.00%
EPS Growth Forecast37.10%